IMMUTEP Ltd (NASDAQ: PRRUF)

Immutep Ltd, a biotechnology company with the ticker symbol IMMP, operates in the immunotherapy industry. Immutep is a pioneer in the field of Lymphocyte Activation Gene-3 (LAG-3), specializing in the development of novel LAG-3 related immunotherapies for cancer and autoimmune diseases.

Immutep's main business activities revolve around the development of its diversified product portfolio, harnessing LAG-3's unique ability to modulate the body's immune response. The company's lead clinical candidate is Eftilagimod Alpha ("Efti" or "IMP321"), an antigen-presenting cell (APC) agonist designed to leverage LAG-3's ability to drive the adaptive and innate immune systems against cancer. Immutep's pipeline includes four product candidates: Efti (IMP321), IMP761, IMP701, and IMP731.

Efti is being evaluated in multiple clinical trials, including TACTI-mel, TACTI-002, TACTI-003, and TACTI-004. These trials are designed to assess the safety and efficacy of Efti in various stages and types of cancer. For instance, TACTI-mel is a Phase I study evaluating the safety and efficacy of Efti in combination with pembrolizumab in melanoma patients. Similarly, TACTI-002 is a Phase II study evaluating the safety and efficacy of Efti in combination with pembrolizumab in patients with head and neck squamous cell carcinoma and non-small cell lung cancer.

Immutep generates revenue through the development and licensing of its LAG-3 technology to pharmaceutical partners, including Merck Serono. The company also conducts its own clinical trials and has received several designations from regulatory authorities, including Fast Track designation from the US Food and Drug Administration (FDA) for Efti in combination with pembrolizumab in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.

In terms of competition, Immutep competes with other biotechnology companies and academic research institutions developing immunotherapies for cancer and autoimmune diseases. However, Immutep's focus on LAG-3 related immunotherapies provides a unique competitive advantage.

Immutep has administrative offices in Sydney, Australia, Leipzig, and Berlin, Germany, and a laboratory near Paris, France. The company employs 41 people and makes extensive use of outside contractors and consultants to manage and conduct manufacturing and clinical trials.